These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15027453)

  • 1. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations.
    Wang SS; Smith JJ
    Food Drug Law J; 2003; 58(4):613-27. PubMed ID: 15027453
    [No Abstract]   [Full Text] [Related]  

  • 2. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of international drug approval systems on confidentiality of business secrets in the U.S. pharmaceutical industry.
    O'Reilly JT
    Food Drug Law J; 1998; 53(1):123-32. PubMed ID: 11795328
    [No Abstract]   [Full Text] [Related]  

  • 4. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

  • 5. The blind hog and the acorn: Medicare coverage for investigational devices.
    Betz R
    J Healthc Resour Manag; 1995 Mar; 13(3):31-2. PubMed ID: 10154864
    [No Abstract]   [Full Text] [Related]  

  • 6. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technology: drug and device export reform.
    Betz R
    J Healthc Resour Manag; 1995 Oct; 13(10):30, 33. PubMed ID: 10151686
    [No Abstract]   [Full Text] [Related]  

  • 8. Exploring options for improving healthcare.
    Wang SS; Mendelson DN; Schulman KA; Mark DB
    Am Heart J; 2004 Jan; 147(1):23-30. PubMed ID: 14691414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disconnect between the HCFA and the FDA.
    Firth BG
    J Invasive Cardiol; 2001 Feb; 13(2):136-8; discussion 158-70. PubMed ID: 11176025
    [No Abstract]   [Full Text] [Related]  

  • 10. Import for export; reporting and recordkeeping requirements for unapproved or violative products imported for further processing or incorporation and subsequent export--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(226):64930-7. PubMed ID: 10338872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Median approval times for class III medical devices have been well above statutory deadlines set for FDA and CMS.
    Zinn AM; Allen JC; Hacker CS
    Health Aff (Millwood); 2012 Oct; 31(10):2304-13. PubMed ID: 23048112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future state of FDA-CMS parallel reviews.
    Messner DA; Tunis SR
    Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the U.S. Food and Drug Administration act against global frauds? The extraterritorial effect of Food and Drug Administration sanctions after Small v. United States.
    O'Reilly J
    Food Drug Law J; 2005; 60(3):347-60. PubMed ID: 16304742
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From proposal to patient: how CMS makes coverage decisions.
    Turnbull GB
    Ostomy Wound Manage; 2002 Apr; 48(4):8-10, 82. PubMed ID: 11993063
    [No Abstract]   [Full Text] [Related]  

  • 16. Already feeling the heat: Docs rethinking payments as Sunshine Act looms.
    Lee J
    Mod Healthc; 2013 Jul; 43(26):12-3. PubMed ID: 23878901
    [No Abstract]   [Full Text] [Related]  

  • 17. Considering changes to CMS's national coverage decision process: applying lessons learned from FDA as a regulator of access to healthcare technology.
    Zalesky CD
    Food Drug Law J; 2002; 57(1):73-93. PubMed ID: 12118482
    [No Abstract]   [Full Text] [Related]  

  • 18. Knowing When and How to Use Medical Products: A Shared Responsibility for the FDA and CMS.
    Califf RM; Sherman RE; Slavitt A
    JAMA; 2016 Dec; 316(23):2485-2486. PubMed ID: 27820637
    [No Abstract]   [Full Text] [Related]  

  • 19. What a Food and Drug lawyer should know about the Medicare Modernization Act.
    Azar AM
    Food Drug Law J; 2004; 59(2):217-22. PubMed ID: 15318393
    [No Abstract]   [Full Text] [Related]  

  • 20. Supplemental standards of ethical conduct and financial disclosure requirements for employees of the Department of Health and Human Services. Interim final rule with request for comments.
    Department of Health and Human Services (HHS)
    Fed Regist; 2005 Feb; 70(22):5543-65. PubMed ID: 15690579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.